Nanomedicines in B cell-targeting therapies

Wang, Jiawei; Yang, Jiyuan; Kopeček, Jindřich

doi:10.1016/j.actbio.2021.10.024

Cited by 14 publications

(8 citation statements)

References 300 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B cells are the center of humoral immunity and can be activated, amplified, and secrete protective antibodies that respond to immunization. At the same time, B cells are also APCs that can present antigens following their recognition via surface of B cell receptors 29 . The bone marrow is the main source of B cells.…”

Section: Impact Of Immunosenescence On Vaccine Efficacymentioning

confidence: 99%

Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies

Hou,

Chen,

Bian

et al. 2024

npj Vaccines

View full text Add to dashboard Cite

Immunosenescence increases the risk and severity of diseases in elderly individuals and leads to impaired vaccine-induced immunity. With aging of the global population and the emerging risk of epidemics, developing adjuvants and vaccines for elderly individuals to improve their immune protection is pivotal for healthy aging worldwide. Deepening our understanding of the role of immunosenescence in vaccine efficacy could accelerate research focused on optimizing vaccine delivery for elderly individuals. In this review, we analyzed the characteristics of immunosenescence at the cellular and molecular levels. Strategies to improve vaccination potency in elderly individuals are summarized, including increasing the antigen dose, preparing multivalent antigen vaccines, adding appropriate adjuvants, inhibiting chronic inflammation, and inhibiting immunosenescence. We hope that this review can provide a review of new findings with regards to the impacts of immunosenescence on vaccine-mediated protection and inspire the development of individualized vaccines for elderly individuals.

show abstract

Section: Impact Of Immunosenescence On Vaccine Efficacymentioning

confidence: 99%

Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies

Hou,

Chen,

Bian

et al. 2024

npj Vaccines

View full text Add to dashboard Cite

show abstract

“…B cells also contribute to adaptive immune responses by functioning as professional APCs 54 , which is often overlooked. B cells recognize antigens through B cell receptors (BCRs) with high affinity 55 , enabling B cells to capture and process antigens in settings of low antigen abundance compared with other APCs. Moreover, B cells exert a multifunctional immune effect, such as presenting antigens, secreting antibodies and cytokines, and even directly inducing tumor cell lysis 56 .…”

Section: Vaccine Delivery Strategymentioning

confidence: 99%

Advanced subunit vaccine delivery technologies: From vaccine cascade obstacles to design strategies

Hou

Chen

Bian

et al. 2023

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“…In the past few years, there have been may reviews written on the subjects contained in this manuscript, i.e., cancer immunotherapy and the use of nanotechnology in this quest. A search of the Web of Science using the terms “Cancer” “Immunotherapy” and “Review” reveals more than 17,000 articles, with >30 of them to be published in the year 2022 (the year after this review is being written()!… These references are relevant to this review ( 124 – 140 )). The purpose of this review is thus to concentrate specifically on what may be the most useful technology developments in the last 5-7 years, focusing only on the use of nanoparticles in tumor immunotherapy approaches, as opposed to simple drug delivery and nano-platform development.…”

Section: Glycoconjugates Antitumor Therapy and Nanotechnologymentioning

confidence: 99%

Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates

Barchi

2022

Front. Immunol.

View full text Add to dashboard Cite

For many years, cell-surface glycans (in particular, Tumor-Associated Carbohydrate Antigens, TACAs) have been the target of both passive and active anticancer immunotherapeutic design. Recent advances in immunotherapy as a treatment for a variety of malignancies has revolutionized anti-tumor treatment regimens. Checkpoint inhibitors, Chimeric Antigen Receptor T-cells, Oncolytic virus therapy, monoclonal antibodies and vaccines have been developed and many approvals have led to remarkable outcomes in a subset of patients. However, many of these therapies are very selective for specific patient populations and hence the search for improved therapeutics and refinement of techniques for delivery are ongoing and fervent research areas. Most of these agents are directed at protein/peptide epitopes, but glycans–based targets are gaining in popularity, and a handful of approved immunotherapies owe their activity to oligosaccharide targets. In addition, nanotechnology and nanoparticle-derived systems can help improve the delivery of these agents to specific organs and cell types based on tumor-selective approaches. This review will first outline some of the historical beginnings of this research area and subsequently concentrate on the last 5 years of work. Based on the progress in therapeutic design, predictions can be made as to what the future holds for increasing the percentage of positive patient outcomes for optimized systems.

show abstract

Nanomedicines in B cell-targeting therapies

Cited by 14 publications

References 300 publications

Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies

Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies

Advanced subunit vaccine delivery technologies: From vaccine cascade obstacles to design strategies

Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates

Contact Info

Product

Resources

About